 Patients were randomized to receive a premixed human insulin formulation with 70 intermediate insulin plus 30 regular insulin Mixtard 30, Novo Nordisk or a basal-bolus regimen with glargine once daily and glulisine before meals Lantus and Apidra, Sanofi-Aventis. 